International Journal of Colorectal Disease

, Volume 23, Issue 2, pp 189–194 | Cite as

Cholestyramine—a useful adjunct for the treatment of patients with fecal incontinence

  • Jose M. Remes-Troche
  • Ramazan Ozturk
  • Carrie Philips
  • Mary Stessman
  • Satish S. C. Rao
Original Article



Cholestyramine may improve fecal incontinence, but its use has not been assessed. We report our experience with the use of cholestyramine in the treatment of fecal incontinence.

Materials and methods

Twenty-one patients (19 female, mean age 65 years) with fecal incontinence (≥1 episode/week) received cholestyramine along with biofeedback therapy (group A). Stool frequency, stool consistency (Bristol scale), number of incontinent episodes, satisfaction with bowel function (VAS), and anorectal physiology were assessed at 3 months and at 1 year after treatment. Data were compared with a matched group of 21 incontinent subjects (19 female, mean age 64 years) who received biofeedback alone (group B).


At 3 months and at 1 year, group A patients showed decreased stool frequency (p < 0.01), stool consistency (p = 0.001), and number of incontinent episodes (p < 0.04). In contrast, stool frequency (p = 0.8) and stool consistency (0.23) were not different from baseline in group B subjects. In both groups, there was improvement in the satisfaction with bowel function (p < 0.05), anal sphincter pressures (p < 0.05) and ability to retain saline infusion (p < 0.05). Mean dose of cholestyramine used was 3.6 g; 13 subjects (62%) required dose titration, and 7 (33%) subjects reported minor side effects.


Cholestyramine is safe and useful adjunct for the treatment of diarrhea and fecal incontinence. Most patients require small doses, and dose titration is important. The improvement in stool characteristics favors a drug effect, over and above the benefits of biofeedback therapy.


Fecal incontinence Cholestyramine Diarrhea Medical treatment 



We sincerely acknowledge the excellent secretarial assistance of Mrs. Heidi Vekemans.

Grant Support

Dr. Remes-Troche was supported by the AGA, Jon I. Isenberg International Scholar Award; Dr Ozturk was supported by a grant from Department of Health, Turkish Air Force, Ankara; and Dr Rao was supported in part by grant R01DK57100-03 National Institutes of Health.


  1. 1.
    Rao SS (2004) American College of Gastroenterology Practice Parameters Committee. Diagnosis and management of fecal incontinence. American College of Gastroenterology Practice Parameters Committee. Am J Gastroenterol 99:1585–1604PubMedCrossRefGoogle Scholar
  2. 2.
    Bharucha AE, Zinsmeister AR, Locke GR, Seide BM, McKeon K, Schleck CD, Melton LJ (2005) Prevalence and burden of fecal incontinence: a population-based study in women. Gastroenterology 129:42–49PubMedCrossRefGoogle Scholar
  3. 3.
    Rao SS (2004) Pathophysiology of adult fecal incontinence. Gastroenterology 126(1 Suppl 1):S14–22PubMedCrossRefGoogle Scholar
  4. 4.
    Remes-Troche JM, Rao SS (2006) Defecation disorders: neuromuscular aspects and treatment. Curr Gastroenterol Rep 8:291–299PubMedCrossRefGoogle Scholar
  5. 5.
    Cheetham MJ, Kenefick NJ, Kamm MA (2001) Non-surgical management of faecal incontinence. Hosp Med 62:538–541PubMedGoogle Scholar
  6. 6.
    Rao SS (1998) The technical aspects of biofeedback therapy for defecation disorders. Gastroenterologist 6:96–103PubMedGoogle Scholar
  7. 7.
    Madoff RD (2004) Surgical treatment options for fecal incontinence. Gastroenterology 126(Suppl 1):S48–S54PubMedCrossRefGoogle Scholar
  8. 8.
    Bachoo P, Brazzelli M, Grant A (2000) Surgery for faecal incontinence in adults. Cochrane Database Syst Rev 2:CD001757PubMedGoogle Scholar
  9. 9.
    Read M, Read NW, Barber DC, Duthie HL (1982) Effects of loperamide on anal sphincter function in patients complaining of chronic diarrhea with fecal incontinence and urgency. Dig Dis Sci 27:807–14PubMedCrossRefGoogle Scholar
  10. 10.
    Sun WM, Read NW, Verlinden M (1997) Effects of loperamide oxide on gastrointestinal transit time and anorectal function in patients with chronic diarrhea and faecal incontinence. Scand J Gastroenterol 32:34–38PubMedCrossRefGoogle Scholar
  11. 11.
    Harford WV, Krejs GJ, Santa Ana CA, Fordtran JS (1980) Acute effect of diphenoxylate with atropine (Lomotil) in patients with chronic diarrhea and fecal incontinence. Gastroenterology 78:440–443PubMedGoogle Scholar
  12. 12.
    Cheetham MJ, Kamm MA, Phillips RK (2001) Topical phenylephrine increases anal canal resting pressure in patients with faecal incontinence. Gut 48:356–359PubMedCrossRefGoogle Scholar
  13. 13.
    Santoro GA, Eitan BZ, Pryde A, Bartolo DC (2000) Open study of low-dose amitriptyline in the treatment of patients with idiopathic fecal incontinence. Dis Colon Rectum 43:1676–1681PubMedCrossRefGoogle Scholar
  14. 14.
    Kusunoki M, Shohji Y, Ikeuchi H, Yamagata K, Yamamura T, Utsunomiya J (1990) Usefulness of valproate sodium for treatment of incontinence after ileoanal anastomosis. Surgery 107:311–315PubMedGoogle Scholar
  15. 15.
    Donnelly V, O'Connell PR, O'Herlihy C (1997) The influence of oestrogen replacement on faecal incontinence in postmenopausal women. Br J Obstet Gynaecol 104:311–315PubMedGoogle Scholar
  16. 16.
    Sinha L, Liston R, Testa HJ, Moriarty KJ (1997) Idiopathic bile acid malabsorption: qualitative and quantitative clinical features and response to cholestyramine. Aliment Pharmacol Ther 12:839–844CrossRefGoogle Scholar
  17. 17.
    Ung KA, Gillberg R, Kilander A, Abrahamsson H (2000) Role of bile acids and bile acid binding agents in patients with collagenous colitis. Gut 46:170–175PubMedCrossRefGoogle Scholar
  18. 18.
    Gotz VP, Rand KH (1982) Medical management of antimicrobial-associated diarrhea and colitis. Pharmacotherapy 2:100–109PubMedGoogle Scholar
  19. 19.
    O’Donell LJD, Virjee J, Heaton KW (1990) Detection of pseudodiarrhea by simple clinical assessment of intestinal transit rate. Br Med J 300:439–440CrossRefGoogle Scholar
  20. 20.
    Rao SSC, Hatfield R, Soffer E, Rao S, Beaty J, Conklin JL (1999) Manometric tests of anorectal function in healthy adults. Am J Gastroenterol 94:773–783PubMedCrossRefGoogle Scholar
  21. 21.
    Rao SS, Welcher KD, Happel J (1996) Can biofeedback therapy improve anorectal function in fecal incontinence. Am J Gastroenterol 91:2360–2366PubMedGoogle Scholar
  22. 22.
    Jacobsen O, Hojgaard L, Hylander Moller E, Wielandt TO, Thale M, Jarnum S, Krag F (1985) Effect of enterocoated cholestyramine on bowel habit after ileal resection: a double blind crossover study. Br Med J (Clin Res Ed) 290(6478):1315–1318Google Scholar
  23. 23.
    Ozturk R, Niazi S, Stessman M, Rao SS (2004) Long-term outcome and objective changes of anorectal function after biofeedback therapy for faecal incontinence. Aliment Pharmacol Therp 20:667–674CrossRefGoogle Scholar
  24. 24.
    Chiarioni G, Bassoti G, Stanganini S, Vantini I Whitehead WE (2002) Sensory retraining is key to biofeedback therapy for formed stool fecal incontinence. Am J Gastroenterol 97:109–117PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Jose M. Remes-Troche
    • 1
  • Ramazan Ozturk
    • 1
  • Carrie Philips
    • 1
  • Mary Stessman
    • 1
  • Satish S. C. Rao
    • 1
    • 2
  1. 1.Section of Neurogastroenterology, Division of Gastroenterology-Hepatology, Department of Internal MedicineUniversity of Iowa Carver College of MedicineIowa CityUSA
  2. 2.University of Iowa Hospital & ClinicsIowa CityUSA

Personalised recommendations